Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clotet; Nathan Clumeck; Ya-Pei Liu; Lijie Zhong; Nicolas Margot; Andrew K Cheng; Steven L Chuck

doi:10.1016/s1473-3099(11)70249-3

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(11)70249-3 ◽

2012 ◽

Vol 12 (1) ◽

pp. 27-35 ◽

Cited By ~ 129

Author(s):

Jean-Michel Molina ◽

Anthony LaMarca ◽

Jaime Andrade-Villanueva ◽

Bonaventura Clotet ◽

Nathan Clumeck ◽

...

Keyword(s):

Protease Inhibitor ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Hiv 1

Download Full-text

Editorial Comment to Efficacy and safety of tadalafil 5 mg once‐daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double‐blind, parallel, placebo‐ and tamsulosin‐controlled study

International Journal of Urology ◽

10.1111/iju.13833 ◽

2018 ◽

Vol 26 (2) ◽

pp. 200-201

Author(s):

Takeya Kitta

Keyword(s):

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Urinary Tract Symptoms ◽

Asian Men ◽

Lower Urinary

Download Full-text

286 Efficacy and Safety of Once Daily Linaclotide Administered Orally for 12-Weeks in Patients With Chronic Constipation: Results From 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

Gastroenterology ◽

10.1016/s0016-5085(10)60244-2 ◽

2010 ◽

Vol 138 (5) ◽

pp. S-53-S-54 ◽

Cited By ~ 4

Author(s):

Anthony Lembo ◽

Harvey Schneier ◽

Bernard J. Lavins ◽

Steven J. Shiff ◽

James E. MacDougall ◽

...

Keyword(s):

Chronic Constipation ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of tadalafil 5 mg once‐daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double‐blind, parallel, placebo‐ and tamsulosin‐controlled study

International Journal of Urology ◽

10.1111/iju.13828 ◽

2018 ◽

Vol 26 (2) ◽

pp. 192-200 ◽

Cited By ~ 8

Author(s):

Zhichao Zhang ◽

Hanzhong Li ◽

Xiaodong Zhang ◽

Yutian Dai ◽

Hyun Jun Park ◽

...

Keyword(s):

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Urinary Tract Symptoms ◽

Asian Men ◽

Lower Urinary

Download Full-text

Efficacy and Safety of Once-daily Linaclotide Administered Orally for 12-weeks in Patients with Chronic Constipation and at Least Moderate Bloating at Baseline: Pooled Results from 2 Randomized, Double-blind, Placebo-controlled Phase 3 Trials

The American Journal of Gastroenterology ◽

10.14309/00000434-201110002-01325 ◽

2011 ◽

Vol 106 ◽

pp. S506-S507 ◽

Cited By ~ 1

Author(s):

Anthony Lembo ◽

Harvey Schneier ◽

Bernard Lavins ◽

Steven Shiff ◽

Xinming Hao ◽

...

Keyword(s):

Chronic Constipation ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study

Cardiology and Therapy ◽

10.1007/s40119-020-00200-8 ◽

2020 ◽

Vol 9 (2) ◽

pp. 505-521

Author(s):

Ajit Mullasari ◽

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Systolic Dysfunction ◽

Immediate Release ◽

Prolonged Release ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Release Formulation ◽

Once Daily

Download Full-text

Efficacy and Safety of Once Daily Linaclotide in Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Followed by a 4-Week Randomized Withdrawal Period

Gastroenterology ◽

10.1016/s0016-5085(11)60561-1 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-138 ◽

Cited By ~ 3

Author(s):

Satish Rao ◽

Anthony Lembo ◽

Steven J. Shiff ◽

Kelvin Shi ◽

Jeffrey M. Johnston ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Efficacy And Safety ◽

Withdrawal Period ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Irritable Bowel

Download Full-text

Efficacy and Safety of Once-Daily Linaclotide Administered Orally for 26 Weeks in Patients With IBS-C: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Gastroenterology ◽

10.1016/s0016-5085(11)60550-7 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-135 ◽

Cited By ~ 5

Author(s):

William D. Chey ◽

Anthony Lembo ◽

James E. MacDougall ◽

Bernard J. Lavins ◽

Harvey Schneier ◽

...

Keyword(s):

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in ART-naïve HIV-1-infected adults to evaluate the efficacy and safety of DRV/Cobi/FTC/TAF versus DRV/Cobi plus FTC/TDF

10.26226/morressier.5aeaf2d35800a00019097fb8 ◽

2018 ◽

Author(s):

Ulrich Meyer-Bunsen

Keyword(s):

Double Blind Trial ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Blind Trial ◽

Hiv 1

Download Full-text

Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis

Gastroenterology ◽

10.1016/s0016-5085(14)62675-5 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-738 ◽

Cited By ~ 7

Author(s):

Eiji Umegaki ◽

Katsuhiko Iwakiri ◽

Naoki Hiramatsu ◽

Yuuichi Sakurai ◽

Tetsuharu Hori ◽

...

Keyword(s):

Multicenter Study ◽

Maintenance Treatment ◽

Erosive Esophagitis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily

Download Full-text

Efficacy and Safety of Once-daily Linaclotide Administered Orally for 12 Weeks to Patients with IBS-C: Pooled Results from Two Randomized, Double-blind, Placebo-Controlled Phase 3 Trials: 2011 ACG Presidential Poster

The American Journal of Gastroenterology ◽

10.14309/00000434-201110002-01322 ◽

2011 ◽

Vol 106 ◽

pp. S504-S505 ◽

Cited By ~ 1

Author(s):

William Chey ◽

Satish Rao ◽

Anthony Lembo ◽

James Shao ◽

Kelvin Shi ◽

...

Keyword(s):

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text